Travere insider plans $6.9M stock sale

Notice under Rule 144 reports Eric Dube’s option-related resale of Travere Therapeutics common stock and recent 10b5-1 sales activity.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) is the issuer for a planned resale of common stock reported by Eric Dube under Rule 144. The notice covers up to 108,493 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, based on an aggregate market value of $6,887,135.64 and referencing 94,261,082 shares outstanding on September 17, 2026.

The shares to be sold are tied to an exercise of stock options on September 17, 2026, for cash. The filing also lists prior 10b5-1 sales of Travere common stock for Eric Dube over the past three months.

Key Figures

Shares to be sold under Rule 144: 108,493 shares Aggregate market value of shares to be sold: $6,887,135.64 Shares outstanding: 94,261,082 shares +3 more

6 metrics

Shares to be sold under Rule 144 108,493 shares Common stock tied to option exercise, as of September 17, 2026

Aggregate market value of shares to be sold $6,887,135.64 Planned Rule 144 sale of 108,493 shares

Shares outstanding 94,261,082 shares Travere Therapeutics common stock as referenced on September 17, 2026

Recent 10b5-1 sale on September 16, 2026 195,841 shares for $12,425,249.75 Eric Dube 10b5-1 sale of common stock

Recent 10b5-1 sale on September 15, 2026 95,666 shares for $5,955,801.63 Eric Dube 10b5-1 sale of common stock

Planned sale date September 17, 2026 Date tied to Rule 144 sale and option exercise

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for ERIC DUBE500 WALNUT ST 3611 Valley Centre Drive"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/17/2026 | Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Travere Therapeutics (TVTX) disclose in this Form 144?

The notice states that Eric Dube may sell up to 108,493 shares of Travere Therapeutics common stock under Rule 144, related to an exercise of stock options on September 17, 2026, with Morgan Stanley Smith Barney LLC as the broker.

How many Travere Therapeutics (TVTX) shares are covered by this planned Rule 144 sale?

The filing covers up to 108,493 shares of Travere Therapeutics common stock, with an aggregate market value of $6,887,135.64, referenced against 94,261,082 shares outstanding as of September 17, 2026.

What is the source of the Travere Therapeutics (TVTX) shares to be sold?

The shares reported in the notice are associated with an exercise of stock options on September 17, 2026, with the exercise described as being for cash and the securities identified as common stock of Travere Therapeutics.

Which broker is listed for the Travere Therapeutics (TVTX) Rule 144 sale?

The notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza in New York, as the broker handling the potential sale of 108,493 shares of Travere Therapeutics common stock.

What recent 10b5-1 sales of Travere Therapeutics (TVTX) stock are disclosed?

The filing lists 10b5-1 sales for Eric Dube of 195,841 shares of common stock on September 16, 2026 for $12,425,249.75, and 95,666 shares on September 15, 2026 for $5,955,801.63.

How many Travere Therapeutics (TVTX) shares were outstanding as referenced in the notice?

The notice references 94,261,082 shares outstanding of Travere Therapeutics common stock as of September 17, 2026; this is presented as a context figure, not as the amount being sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:36 PM Accepted by SEC EDGAR 09/17/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001763494
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS INC
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	ERIC DUBE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	108493	6887135.64	94261082	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2026	Exercise of Stock Options	Issuer			108493	09/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ERIC DUBE500 WALNUT ST 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	09/16/2026	195841	12425249.75
10b5-1 Sales for ERIC DUBE500 WALNUT ST 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	09/15/2026	95666	5955801.63

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Dube
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)